Pablo Jordan

Pablo Jordan serves as CEO at Dreampath Diagnostics. Dreampath Diagnostics operates in the medical devices sector with approximately 44.0 employees. The company is headquartered in Madrid, Community of Madrid.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • 2,039 executive contacts are available in Community of Madrid.
• • Our database includes 201,469 c suite-level executives.

Mailchimp Mandrill Outlook Mobile Friendly reCAPTCHA Google Tag Manager Google Analytics YouTube Google Font API Apache WordPress.org Android Remote AI Circle

sample management sample traceability tissue block archiving slide management patient safety automation workflow improvement laboratory efficiency fina system crystal system hydra system anatomic pathology error reduction manual sorting elimination precise retrieval tissue processing chain of custody barcoding data tracking tissue sample storage laboratory information systems case turnaround time sample access patient care error prevention laboratory productivity resource allocation tissue sample tracking clinical trials sample retrieval digital pathology workflow optimization cost reduction staff retention quality assurance process automation research support mobile scanning inventory management specimen tracking protocol compliance workflow analytics time-saving solutions medical diagnostics anatomical pathology solutions scanning technology data management multi-location storage workforce efficiency tissue processing efficiency health care health wellness & fitness hospital & health care

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like Pablo Jordan in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Dreampath Diagnostics.

Pablo Jordan's Position in the MessageCEO Database

• •Pablo Jordan is 1 of 1 verified executive contact we track at Dreampath Diagnostics.
• •1,787 verified executive contacts in medical devices are in the MessageCEO database.
• •2,023 verified executive contacts in Community of Madrid are in the database.
• •19 verified contacts work at medical devices companies in the 44.0 employee range (same size as Dreampath Diagnostics).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated June 2026.

How do I reach Pablo Jordan directly?

Pablo Jordan's verified email address is available to MessageCEO Pro subscribers. They currently serve as CEO at Dreampath Diagnostics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Pablo Jordan work for?

Pablo Jordan is CEO at Dreampath Diagnostics, a company in the medical devices sector with 44.0 employees. The company is based in Madrid, Community of Madrid.

Can I pitch or sell to Pablo Jordan?

As CEO at Dreampath Diagnostics, Pablo Jordan is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach Pablo Jordan directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Pablo Jordan in?

Pablo Jordan works in the medical devices industry as CEO at Dreampath Diagnostics. MessageCEO provides verified contact information for executives across all major industries.

Is Pablo Jordan's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Pablo Jordan's profile is kept up-to-date with the latest available information.

Last updated: June 20, 2026